Under the terms of the agreement, CICT will utilize Cesca’s newest evolution of the AutoXpress® platform under the Company’s "Early Technology Access Program". Specifically, this latest innovation of
These formulations will be compared against an immediate release oral solution of drug candidate OCR-002 and ammonia-lowering agent glycerol phenylbutrate (RAVICTI®), a pre-pro drug of phenylacetate, a component
The granted claims of the patents include the class of selective alpha-4-beta-2 compounds discovered by Suven and are being developed as therapeutic agents for major depressive disorder (MDD).
The Phase 1 study is being performed in asymptomatic "high excreter" (ASHE) patients, who carry the genetic mutation of acute intermittent porphyria (AIP) and have elevated levels of
Andexanet alfa, a U.S. Food and Drug Administration (FDA)-designated breakthrough therapy, is a recombinant protein specifically designed to reverse the anticoagulant activity of Factor Xa inhibitors. Portola is
This registration study enrolled approximately 220 patients at approximately 75 sites in North America, Europe and Asia. ARIAD president of research and development and chief scientific officer Timothy
Alector has built a broad platform of new-generation therapeutics, which mobilize the immune system to eliminate multiple disease-causing pathologies. Alector co-founder Asa Abeliovich said: "We have developed a
The product line provides a full assortment of hospital-quality products for consumers categorized as Advanced Wound Care, First Aid, Personal Care, and Home Healthcare which help provide comfort
The MAA for GRASPA, ERYTECH’s lead product, consisting of asparaginase encapsulated in red blood cells, is based on the positive findings of the pivotal GRASPALL 2009-06 Phase 2/3
There is no set expiration date for the program. The Company intends to use cash on hand, cash generated from operations, existing credit facilities or other financing to
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.